New Treatment Modalities in Hemophilia
Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder. Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy....
Saved in:
| Main Author: | Kaan Kavaklı |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aydın Pediatric Society
2022-03-01
|
| Series: | Trends in Pediatrics |
| Subjects: | |
| Online Access: | https://trendspediatrics.com/article/view/42 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center
by: Qianqian Mao, et al.
Published: (2024-12-01) -
TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab
by: Teruhisa Fujii, et al.
Published: (2025-07-01) -
Successful Perioperative Management of Titanium Cranioplasty in a Patient with Severe Hemophilia A
by: Gabriela Micurova, et al.
Published: (2025-04-01) -
Progressive cephalohematoma in a neonate revealing severe hemophilia a owing to intron 22 inversion: a case report
by: Cheng Peng, et al.
Published: (2025-07-01) -
Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII
by: Sylvain Lamoine, et al.
Published: (2024-10-01)